Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia

Cancer Letters

Volumn 360, Issue 1, 2015, Pages 28-38

  Shinohara, Haruka ^a   Taniguchi, Kohei ^a   Kumazaki, Minami ^a   Yamada, Nami ^a   Ito, Yuko ^b   Otsuki, Yoshinori ^b   Uno, Bunji ^c   Hayakawa, Fumihiko ^d   Minami, Yosuke ^e   Naoe, Tomoki ^f   Akao, Yukihiro ^a  

^a GIFU UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KOBE UNIVERSITY HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Autophagy; Bcr abl; Cell death; Fatty acid derivative; Warburg effect

Indexed keywords

1 (AZOCAN 1 YL) DEC 3 EN 1 ONE; ANTINEOPLASTIC AGENT; FATTY ACID DERIVATIVE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRUVATE KINASE; PYRUVATE KINASE M; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ABL-BCR FUSION PROTEIN, HUMAN; BCR ABL PROTEIN; BETA CATENIN; CARRIER PROTEIN; CTNNB1 PROTEIN, HUMAN; FATTY ACID; ISOENZYME; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; MYC PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TARGET OF RAPAMYCIN KINASE; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

ARTICLE; AUTOPHAGY; BCR ABL GENE; CELL DEATH; CHROMATIN IMMUNOPRECIPITATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ELECTRON MICROSCOPY; ELECTRON SPIN RESONANCE; ENERGY METABOLISM; FUSION GENE; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; K562 CELL LINE; METABOLISM; PATHOLOGY; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; BETA CATENIN; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; FATTY ACIDS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; ISOENZYMES; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE PROTEINS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-MYC; PYRUVATE KINASE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID HORMONES; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84924499024     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.039     Document Type: Article

References (31)

1. Skorski T., Kanakaraj P., Nieborowska-Skorska M., Ratajczak M.Z., Wen S.C., Zon G., et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995, 86:726-736.
2. Sheng Z., Ma L., Sun J.E., Zhu L.J., Green M.R. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 2011, 118:2840-2848.
3. Carayol N., Vakana E., Sassano A., Kaur S., Goussetis D.J., Glaser H., et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:12469-12474.
4. Cilloni D., Saglio G. Molecular pathways: BCR-ABL. Clin. Cancer Res 2012, 18:930-937.
5. Modugno M. New resistance mechanisms for small molecule kinase inhibitors of Abl kinase. Drug Discov. Today Technol 2014, 11:5-10.
6. Sun Q., Chen X., Ma J., Peng H., Wang F., Zha X., et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4129-4134.
7. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
8. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
9. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
10. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
11. David C.J., Chen M., Assanah M., Canoll P., Manley J.L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
12. Clower C.V., Chatterjee D., Wang Z., Cantley L.C., Vander Heiden M.G., Krainer A.R. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1894-1899.
13. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
14. Zurlo D., Assante G., Moricca S., Colantuoni V., Lupo A. Cladosporol A, a new peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, inhibits colorectal cancer cells proliferation through beta-catenin/TCF pathway inactivation. Biochim. Biophys. Acta 1840, 2014:2361-2372.
15. Shinohara H., Noguchi S., Kumazaki M., Yamada N., Ito T., Oyama M., et al. 3-Decenoic acid derivatives induce autophagic cell death through the down-regulation of E2F1. J. Toxicol. Res 2013, 3:29-34.
16. Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H., et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol. Cell 2012, 48:667-680.
17. Niso-Santano M., Shen S., Adjemian S., Malik S.A., Marino G., Lachkar S., et al. Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. Autophagy 2013, 9:415-417.
18. Palomer X., Capdevila-Busquets E., Botteri G., Salvado L., Barroso E., Davidson M.M., et al. PPARbeta/delta attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells. Int. J. Cardiol 2014, 174:110-118.
19. Rovito D., Giordano C., Vizza D., Plastina P., Barone I., Casaburi I., et al. Omega-3 PUFA ethanolamides DHEA and EPEA induce autophagy through PPARgamma activation in MCF-7 breast cancer cells. J. Cell. Physiol 2013, 228:1314-1322.
20. Waku T., Shiraki T., Oyama T., Fujimoto Y., Maebara K., Kamiya N., et al. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids. J. Mol. Biol 2009, 385:188-199.
21. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem 2009, 30:2785-2791.
22. Yoshimori T., Yamamoto A., Moriyama Y., Futai M., Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J. Biol. Chem 1991, 266:17707-17712.
23. Yamamoto A., Tagawa Y., Yoshimori T., Moriyama Y., Masaki R., Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct 1998, 23:33-42.
24. Scherz-Shouval R., Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol 2007, 17:422-427.
25. Scherz-Shouval R., Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem. Sci 2011, 36:30-38.
26. Demaria M., Giorgi C., Lebiedzinska M., Esposito G., D'Angeli L., Bartoli A., et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) 2010, 2:823-842.
27. Hitosugi T., Kang S., Vander Heiden M.G., Chung T.W., Elf S., Lythgoe K., et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal 2009, 2:ra73.
28. Ciarcia R., Damiano S., Montagnaro S., Pagnini U., Ruocco A., Caparrotti G., et al. Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. Cell Cycle 2013, 12:2839-2848.
29. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:4318-4323.
30. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395:137-143.
31. Liberato M.V., Nascimento A.S., Ayers S.D., Lin J.Z., Cvoro A., Silveira R.L., et al. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) gamma activators and pan-PPAR partial agonists. PLoS ONE 2012, 7:e36297.